Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium hyaluronate + lidocaine is a combination therapy evaluated for the treatment of chronic subacromial bursitis. The formulation specifically utilizes **ARTZ**, a 1% sodium hyaluronate solution with a molecular weight of approximately 0.9x10^6 Da, which acts as a viscosupplement to provide mechanical lubrication and shock absorption within the subacromial bursa. Beyond its mechanical properties, sodium hyaluronate exerts anti-inflammatory effects and modulates pain by interacting with cellular receptors. Lidocaine is included in the injection as a local anesthetic to provide immediate symptomatic relief and facilitate the ultrasound-guided procedure. This combination was the subject of a randomized, double-blind, controlled trial (NCT01441401) sponsored by **Shin Kong Wu Ho-Su Memorial Hospital** to compare its efficacy against corticosteroids and placebo in patients with chronic shoulder pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium hyaluronate + lidocaine.